Erika Jones - 18 Nov 2021 Form 3 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Vice President, Finance and Corporate Controller
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
18 Nov 2021
Net transactions value
$0
Form type
3
Filing time
29 Nov 2021, 20:25:28 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 25,502 $10.86 Direct F1
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 10,000 $19.00 Direct F2
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 10,800 $24.84 Direct F3
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 4,500 $7.73 Direct F4
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 4,500 $7.62 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on October 28, 2020, with the reminder vesting in 36 equal monthly installments thereafter.
F2 25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
F3 25% of the shares subject to this option shall vest and become exercisable on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
F4 The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on October 18, 2022.
F5 The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on November 16, 2022.

Remarks:

Officer Title: Vice President, Finance and Corporate Controller